BHVN250117C25000
- 26.35
- 0.000.00%
Biohaven Newsroom
Biohaven Rises 6.1%
Insider Purchase: Director at $BHVN (BHVN) Buys 29,000 Shares
Biohaven Insider Bought Shares Worth $1,042,393, According to a Recent SEC Filing
H.C. Wainwright Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $59
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved With BHV-1300, Gains Analyst Approval
Express News | Cantor Fitzgerald Reiterates Overweight on Biohavento Overweight
Jefferies Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $64
A Quick Look at Today's Ratings for Biohaven(BHVN.US), With a Forecast Between $56 to $69
Express News | HC Wainwright & Co. Reiterates Buy on Biohaven, Maintains $59 Price Target
Is Biohaven Ltd. (BHVN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
Promising Drug Pipeline and Strategic Progress Position Biohaven Ltd. for Growth
Biohaven Ltd.'s Promising Pipeline and Strategic Partnerships Drive Buy Recommendation
Biohaven Reports Clinical, Regulatory Milestones Across MoDE Platform
Biohaven's BHV-1300 Achieves Advances in Targeted IgG Reduction Trials
Express News | Biohaven Ltd - Bhv-1300 Safe and Well Tolerated in Phase 1
Express News | Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted Igg Reductions in the Lowest Subcutaneous Dose Tested; Announces Nda Submission for Troriluzole in SCA and Provides Other Key Program Updates
Lilly Tops Morgan Stanley's Biopharma Pick List for 2025
Biohaven Shares Are Trading Higher After the Company Announced It Will Present Expanded Safety Data From Its BHV-7000 Multiple-dose Studies at the 2024 American Epilepsy Society Annual Meeting.
Biohaven Presents New Data With BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Raises Target Price to $61